Remote monitoring programs for cardiac conditions

Clark A, Sousa B, Smith A, Steele D, Rader T, MacDougall D, Kaunelis D, Mason J, Harris J
Record ID 32018004194
Authors' objectives: Remote monitoring (RM) is a type of telehealth where health care is delivered to patients outside traditional settings by allowing health data to be exchanged between patients and health care providers using telecommunication technologies or stand-alone devices. It has been noted that implementation of RM technologies in Canada is not a question of if it will happen, but rather when and how it will happen. Jurisdictions are faced with the challenge of how best to implement RM programs for patients living in rural, remote, and urban settings. CADTH will undertake an Optimal Use project of RM programs for the management of chronic heart failure, atrial fibrillation, hypertension, and cardiac rehabilitation for acute and chronic conditions. The purpose of the project is to assess the implementation of these RM programs including barriers and facilitators to success, perspectives and experiences of those participating in remote monitoring programs, and ethical considerations. Additional reviews of clinical effectiveness, safety, and economic considerations may also be conducted.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Mini HTA
Country: Canada
MeSH Terms
  • Heart Failure
  • Atrial Fibrillation
  • Telemedicine
  • Hypertension
  • Cardiac Rehabilitation
  • Remote Consultation
  • Monitoring, Physiologic
  • Cardiac Rehabilitation
  • Remote Monitoring
  • Cardiac Conditions
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: <p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.